Pubblicazioni

Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

2022 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Hughes, Timothy P.; Cortes, Jorge E.; Rea, Delphine; Mauro, Michael J.; Hochhaus, Andreas; Kim, Dong-Wook; Sasaki, Koji; Lang, Fabian; Heinrich, Michael C.; Breccia, Massimo; Deininger, Michael; Goh, Yeow-Tee; Janssen, ; Jeroen, J. W. M.; Talpaz, Moshe; le Coutre, Philipp; Kapoor, Shruti; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Mahon, Francois-Xavier

Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Cortes, Jorge E.; Hughes, Timothy P.; Mauro, Michael J.; Hochhaus, Andreas; Rea, Delphine; Goh, Yeow-Tee; Janssen, J. J. W. M.; Heinrich, Michael C.; Talpaz, Moshe; Etienne, Gabriel; Breccia, Massimo; Deininger, Michael; Le Coutre, Philipp; Lang, Fabian; Polydoros, Fotis; Cacciatore, Silvia; Stenson, Laura; Kim, Dong-Wook